platinum bpc 157 BPC-157 Injectable Peptide for Healing & Recovery BPC-157 (10mg) for Research |

On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list

Validated assay content: 10.26 mg with purity greater than 99.8 percent

Simple cycle review framework Review point Baseline What to check Research goal, measurements, route, and materials Reason Creates a clear starting point Review point Week 4 What to check Tolerance, handling, and protocol consistency Reason Finds early problems Review point Week 8 What to check Trend compared with baseline Reason Tests whether the plan is producing useful data Review point Week 12 What to check Full review of benefits, limits, and uncertainty Reason Prevents an automatic extension Review point Week 16 or later What to check Reason for continuing and remaining evidence gaps Reason Longer subcutaneous timelines are not clinically established When a Longer Cycle Is Not Supported There is no published evidence showing that extending AOD-9604 beyond 12 or 16 weeks improves the outcome of a community subcutaneous plan

But will give it another month to see if I can get better results Excellent I have completed 3 weeks of the first vial and the results have been fantastic